Global resistance trends and the potential impact on empirical therapy

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 4, 2008, Pages

  Isturiz, Raul ^a  

^a Centro Medico Docente La Trinidad   (Venezuela)

Author keywords

Antimicrobial resistance; Broad spectrum antimicrobial agents; Gram negative bacilli; Gram positive cocci; Multidrug resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENOME; BACTERIAL VIRULENCE; CORTICOSTEROID THERAPY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; GRAM NEGATIVE BACTERIUM; HUMAN; KIDNEY FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; RISK FACTOR; SOFT TISSUE INFECTION; TREATMENT INDICATION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 58149165335     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(09)70003-2     Document Type: Article

References (37)

1. Chow J., Fine M., Shlaes D., Quinn J.P., Hooper D.C., Johnson M.P., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Int Med 115 (1991) 585-590
2. Homberg S., Solomon S., and Blake P. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 9 (1987) 1065-1078
3. Bell J.M., and Turnidge J.D. High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob Agents Chemother 46 (2002) 879-881
4. Paterson D.L., Rossi F., Baquero F., Hsueh P.R., Woods G.L., Satishchandran V., et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 55 (2005) 965-973
5. Lesprit P., and Brun-Buisson C. Hospital antibiotic stewardship. Curr Opin Infect Dis 21 (2008) 344-349
6. Eriksen K.R., and Erichsen I. Clinical occurrence of meticillin-resistant strains of Staphylococcus aureus. Ugeskr Laeger 125 (1963) 1234-1240
7. Christiansen K.J., Bell J.M., Turnidge J.D., and Jones R.N. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob Agents Chemother 48 (2004) 2049-2055
8. Ko K.S., Lee J.Y., Suh J.Y., Oh W.S., Peck K.R., Lee N.Y., et al. Distribution of major genotypes among methicillin-resistant Staphylococcus aureus clones in Asian countries. J Clin Microbiol 43 (2005) 421-426
9. Bonten M.J., Willems R., and Weinstein R.A. Vancomycin-resistant enterococci: why are they here, and where do they come from?. Lancet Infect Dis 1 (2001) 314-325
10. Emori T.G., and Gaynes R.P. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 6 (1993) 428-442
11. Edmond M.B., Ober J.F., Weinbaum D.L., Pfaller M.A., Hwang T., Sanford M.D., et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 20 (1995) 1126-1133
12. Linden P.K., Pasculle A.W., Manez R., Kramer D.J., Fung J.J., Pinna A.D., et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 22 (1996) 663-670
13. Shay D.K., Maloney S.A., Montecalvo M., Banerjee S., Wormser G.P., Arduino M.J., et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 172 (1995) 993-1000
14. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., and Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60 (2007) 1018-1029
15. Rodriguez-Baño J., Navarro M.D., Romero L., Muniain M.A., de Cueto M., Ríos M.J., et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43 (2006) 1407-1414
16. Bodmann K.F. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 51 (2005) 227-233
17. Nicolas-Chanoine M.H., Blanco J., Leflon-Guibout V., Demarty R., Alonso M.P., Caniça M.M., et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61 (2008) 273-281
18. Clermont O., Lavollay M., Vimont S., Deschamps C., Forestier C., Branger C., et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 61 (2008) 1024-1028
19. Notka F., Linde H.J., Dankesreiter A., Niller H.H., and Lehn N. A C-terminal 18 amino acid deletion in MarR in a clinical isolate of Escherichia coli reduces MarR binding properties and increases the MIC of ciprofloxacin. J Antimicrob Chemother 49 (2002) 41-47
20. Deguchi T., Yasuda M., Nakano M., Ozeki S., Kanematsu E., Nishino Y., et al. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae. J Antimicrob Chemother 40 (1997) 543-549
21. Pfaller M.A., Jones R.N., and Biedenbach D.J. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 41 (2001) 177-182
22. Livermore D.M., James D., Reacher M., Graham C., Nichols T., Stephens P., et al. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 8 (2002) 473-478
23. Lee K., Lee H.S., Jang S.J., Park A.J., Lee M.H., Song W.K., et al. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and Gram-negative bacilli to third-generation cephalosporin, imipenem, and fluoroquinolone. J Korean Med Sci 16 (2001) 262-270
24. Wang F., Zhu D.M., Hu F.P., and Zhang Y.Y. Surveillance of bacterial resistance among isolates in Shanghai in 1999. J Infect Chemother 7 (2001) 117-120
25. Hsueh P.R., Liu C.Y., and Luh K.T. Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis 8 (2002) 132-137
26. Hsueh P.R., Tseng S.P., Teng L.J., and Ho S.W. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan. Clin Microbiol Infect 11 (2005) 670-673
27. Walther-Rasmussen J., and Høiby N. Class A carbapenemases. J Antimicrob Chemother 60 (2007) 470-482
28. Poirel L., and Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12 (2006) 826-836
29. Walsh T.R. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria. Clin Microbiol Infect 11 Suppl 6 (2005) 2-9
30. Jones R.N., Biedenbach D.J., Sader H.S., Fritsche T.R., Toleman M.A., and Walsh T.R. Emerging epidemic of metallo-beta-lactamase-mediated resistances. Diagn Microbiol Infect Dis 51 (2005) 77-84
31. Tato M., Coque T.M., Ruiz-Garbajosa P., Pintado V., Cobo J., Sader H.S., et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity?. Clin Infect Dis 45 (2007) 1171-1178
32. Woodford N., Dallow J.W., Hill R.L., et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 29 (2007) 456-459
33. Szabó D., Silveira F., Hujer A.M., et al. Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob Agents Chemother 50 (2006) 2833-2835
34. Jacoby G.A., Mills D.M., and Chow N. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 48 (2004) 3203-3206
35. Elliott E., Brink A.J., van Greune J., Els Z., Woodford N., Turton J., et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 42 (2006) e95-e98
36. Segal H., and Elisha B.G. Resistance to β-lactams, and reduced susceptibility to carbapenems, in clinical isolates of Klebsiella pneumoniae due to interplay between CTX-M-15 and altered outer membrane permeability. South Afr J Epidemiol Infect 21 (2006) 41-44
37. Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50 (2006) 2946-2950